Univax Biologics Inc. filed a registration statement with the Securitiesand Exchange Commission to offer 3 million newly issued shares ofcommon stock.Univax, of Rockville, Md., said Tuesday it will sell the stock itself. Itcurrently has about 13 million shares outstanding and, as of June 30,had cash and short-term investments totaling about $18.5 million, IrisKesterman, Univax's corporate communications manager, toldBioWorld. She said Univax (NASDAQ:UNVX) is burning about $1.5million per month. The company's stock closed Tuesday at $6.25 pershare, down 50 cents.The company, with licensing partner Rh Pharmaceuticals Inc. ofWinnipeg, Manitoba, has a product license application (PLA) pendingwith the FDA for WinRho SD. The hyperimmune polyclonal antibodyis for the treatment of chronic and acute idiopathic thrombocytopenicpurpura (ITP) in children and adults, ITP secondary to HIV infection,and prevention of Rh isoimmunization. Last week Univax received anaction letter from the FDA asking for what company officials describedas minor clarifications to the PLA. Analysts said the product could beapproved by the end of the year. _ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.